ArticleAntimicrobial resistance and infection control2025
Carbapenem-resistant Enterobacterales infection and colonization in patients with severe burns: a retrospective cohort study in a single burn center.
Article in Antimicrobial resistance and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Challenges in Antimicrobial Treatment and Antimicrobial Stewardship in Hospital-Acquired Infections in Adult Burn Patients.European burn journal · 2026Review
- Antimicrobial Resistance of ESKAPE Pathogens Identified in Patients with Necrotizing Fasciitis: A 10-Year Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Article
- Rapid Identification of Carbapenemase Genes Directly from Blood Culture Samples.Diagnostics (Basel, Switzerland) · 2025Article
- The potential of the microbiome as a target for prevention and treatment of carbapenem-resistant Enterobacteriaceae infections.Frontiers in cellular and infection microbiology · 2025Review
- Risk Factors and Molecular Epidemiology of Infections Among Patients with Intestinal Colonization by Carbapenem-ResistantInfection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical characteristics and outcomes of carbapenem-resistant Enterobacterales (CRE) infection and colonization have rarely been reported in patients with severe burns, who are prone to severe bacterial infections. This study aimed to evaluate clinical characteristics and outcomes of CRE infection and colonization in patients with severe burns.
methodsThe characteristics of 106 episodes of CRE acquisition (infection or colonization) in 98 patients with severe burns were evaluated by a retrospective medical record review. The duration of rectal CRE colonization and its associated factors were determined in the survived patients.
resultsFive (4.7%) of the CRE acquisitions were identified on admission, and the remaining 101 (95.3%) were identified at a median of 11 days (range 2-75 days) after admission. Klebsiella pneumoniae represented 73.6% of the isolated CRE strains, and carbapenemase-producing CRE (CP-CRE) were identified in 70.8% of the isolates. Mortality was associated with an abbreviated burn severity index (ABSI) score ≥ 10 (p < 0.001) and previous carbapenem-resistant bacterial acquisition (protective, p = 0.010). For the 58 episodes of CRE acquisition in the survived patients, eradication of rectal CRE colonization was identified in 39 (67.2%) at a median of 64 days (range 10-434 days) after acquisition. CP-CRE strains were associated with prolonged rectal CRE colonization (p < 0.001).
conclusionsThe characteristics of CRE infection and colonization in patients with severe burns were similar to those in general critical patients. Enhanced infection prevention and control measures should be considered for patients with severe burns of an ABSI score ≥ 10 and those with CP-CRE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.